A New Cannabis Formula Could Revolutionize Treatment for Epilepsy and MS
What’s the Breakthrough?
Researchers from the University of South Australia have developed a new phospholipid-based CBD complex that could increase CBD solubility by up to six times and improve absorption in the body by over 30%. This development has major implications for the treatment of epilepsy, multiple sclerosis (MS), and other neurological conditions that rely on CBD-based therapies.
Only a small percentage of orally consumed CBD typically reaches the bloodstream due to poor solubility and rapid metabolism. This innovative formula may finally overcome that limitation.
Why CBD Bioavailability Matters
| Problem | Impact |
|---|---|
| CBD is poorly water-soluble | Limits absorption in the digestive tract |
| Low oral bioavailability (~6–10%) | Requires higher doses for therapeutic effect |
| Inconsistent response | Difficult to predict treatment outcomes |
| Increased treatment cost and risk of side effects | Higher quantities needed |
This new CBD–phospholipid complex addresses these issues by encapsulating CBD in a structure that mimics cell membranes, allowing for better solubility and easier absorption through the intestinal lining.
What the Research Shows
- Solubility: CBD solubility increased by up to 6x compared to its raw form
- Absorption: A 32.7% increase in cellular permeability was observed in lab studies
- Stability: The complex remained stable for 12 months under various storage conditions
- Efficiency: Smaller doses could achieve the same or improved therapeutic effects
This means patients could benefit from more reliable and effective outcomes with reduced dosages.
Applications for Epilepsy and Multiple Sclerosis
CBD is already used as an approved treatment for certain forms of epilepsy (e.g., Epidiolex). Improved bioavailability may enhance seizure control with fewer side effects.
For MS patients, CBD is often used to manage muscle spasticity, pain, and inflammation. A more consistent and absorbable formula means better daily management with less variability in results.
Dr. Craig Williams, lead pharmaceutical scientist on the project, stated:
“This is a step forward in making cannabinoid-based medicine truly effective and reliable.”
What’s Next?
The research team is currently:
- Preparing for clinical trials
- Seeking commercial partnerships for pharmaceutical use
- Exploring how this delivery method could be adapted to other cannabinoids, such as THC, CBG, and CBN
If successful, this technique could become a model for improving the effectiveness of a wide range of cannabis-based treatments.
| How the CBD–Phospholipid Complex Enhances Solubility | |
| Multiple Sclerosis Involves Nerve Damage — CBD May Help |
Final Thoughts
Improving the bioavailability of CBD has long been a challenge in the world of cannabinoid-based medicine. This new phospholipid complex could represent a critical turning point, delivering more reliable and efficient therapeutic results with lower dosages and fewer side effects.
For patients suffering from epilepsy, MS, and other neurological conditions, this advancement may offer a safer, more effective way to incorporate CBD into their treatment plans.
Sources :
- University of South Australia : New Cannabis formula will help epilepsy, multiple sclerosis sufferers
- Medical Xpress : New Cannabis formula will help epilepsy
- ResearchGate : Electron Edge Diffraction from Carbon films